04:21 , Dec 9, 2017 |  BioCentury  |  Product Development

Multimodal meeting

This year’s clinical abstracts at the American Society of Hematology meeting hint at how newer treatment modalities -- cell therapies in cancer and gene therapies in hematology -- will branch out into new indications and...
23:28 , Aug 3, 2017 |  BC Innovations  |  Tools & Techniques

Click bait

GlaxoSmithKline plc is developing click chemistry-based systems to pinpoint and quantify how drug candidates target DNA sequences, protein complexes and disease sites. The company believes the "click-probes" could slash failure rates in drug development by...
08:00 , Jan 5, 2015 |  BioCentury  |  Product Development

BETting early

Index Ventures-backed oncology play Oncoethix S.A. traded potentially larger returns for a faster clinical program for the company's primary asset when the Phase II program became too big for the small biotech to handle. On...
07:00 , Sep 18, 2014 |  BC Innovations  |  Cover Story

Neutralizing HIV rebound

Although antiretroviral therapies have transformed HIV infection into a chronically manageable disease, they have made little impact in reaching the latent viral reservoirs that are sources of disease rebound. Researchers at The Rockefeller Universityhave found...
07:00 , May 15, 2014 |  BC Innovations  |  Cover Story

Chromatin's rising tide

To capitalize on the full range of possible chromatin targets in and beyond oncology, industry and academia will need to delve deeper into how chromatin regulation is altered in disease, create tools that can reliably...
07:00 , May 8, 2014 |  BC Innovations  |  Cover Story

BETting on OncoFusion

Medivation Inc. has licensed a portfolio of BET bromodomain inhibitors that could have better efficacy than the company's castration-resistant prostate cancer drug Xtandi enzalutamide and could provide the biotech with a new way to disrupt...
07:00 , Apr 17, 2014 |  BC Innovations  |  Strategy

Expanding into new (bromo)domains

The Neomed Institute has begun development of its first cancer therapeutic, a bromodomain containing 4 inhibitor from Epigenetix Inc. that the not-for-profit organization thinks could have a selectivity advantage over competing molecules. Bromodomain-containing proteins are a...
07:00 , Mar 27, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Acute lymphoblastic leukemia (ALL) Bromodomain containing 4 (BRD4); notch 1 (NOTCH1) Mouse and cell culture studies...
08:00 , Nov 14, 2013 |  BC Innovations  |  Targets & Mechanisms

BETting on Th17 cells

Researchers at Constellation Pharmaceuticals Inc. have established a connection between BET bromodomain proteins and pathogenic T helper type 17 cells.1 The findings hint at therapeutic opportunities for this epigenetic target class in autoimmunity and inflammatory...
07:00 , Oct 17, 2013 |  BC Innovations  |  Strategy

Clinical takeoff for new epigenetic targets

There is little doubt that 2014 will be a banner year for next-generation epigenetics companies, with key clinical data expected for next-generation drugs and first-generation candidates that target new epigenetic regulators. But the big biotech...